Loading
Latest filing published 29 Apr 2026 for 명문제약.
No signal scores available.
Not enough history yet: 0 closed purchases, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
All filings by 이영미 on record concern 명문제약, in the capacity of senior executive. We count 2 filings; the first trade dates from 6 November 2025 and the latest from 28 April 2026.
Every open-market trade on record is a purchase: 2 purchases, and no sale. The totals exclude 2 filings filed without an amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. 2026 to date brings 1 purchase and no sales.
The latest filing, published on 29 April 2026, reports an open-market purchase in 명문제약. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.